Apixaban, a non-vitamin K oral anticoagulant (NOAC), has demonstrated better efficacy and safety characteristics than the VKA warfarin in the ARISTOTLE trial. This study aims to quantify the potential societal effects of using apixaban instead of VKA in the German NVAF population from 2017 to ...
The interaction term was not significant in each model (P > .28). Consequently, the proportional hazard assumption was met. The effect of ICM monitoring was evaluated among the 33 enrolling sites with a post hoc mixed-effects model analysis of the primary end point. Sites were random ...
(ACCP or CHEST) guidelines with which the authors are closely affiliated, we use “long-term” to refer to the period after the first 3 months of treatment (often indefinitely), which has also been referred to as the “extended” or “chronic phase” of therapy (see "How long should ...
We aim to determine the impact of ABC pathway in a contemporary cohort of clinically complex AF patients. Methods From the ESC-EHRA EORP-AF General Long-Term Registry, we analysed clinically complex AF patients, defined as the presence of frailty, multimorbidity and/or polypharmacy. A K-...
Although long-term survival is now the norm, Fontan patients face significant morbidity and premature mortality. Wide variation exists in long-term Fontan
Thrombosis Journal 2014, 12:16 http://www.thrombosisjournal.com/content/12/1/16 ORIGINAL CLINICAL INVESTIGATION Open Access XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis Walter ...
Apixaban, a non-vitamin K oral anticoagulant (NOAC), has demonstrated better efficacy and safety characteristics than the VKA warfarin in the ARISTOTLE trial. This study aims to quantify the potential societal effects of using apixaban instead of VKA in the German NVAF population from 2017 to ...
Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.doi:10.1080/14737167.2019.1522501Non-valvular atrial fibrillation...
LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROESdoi:10.1016/S0735-1097(19)30932-5Alexander BenzJohn EikelboomSalim YusufStefan HohnloserStuart J. ConnollyElsevier BVJournal of the American College of Cardiology
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.doi:10.1055/S-0040-1717115Alexander P. BenzJohn W. EikelboomSalim YusufStefan H. HohnloserAnja KahlHeather Beresh